Gilteritinib

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Adult Indications and Dosage

Plasma Concentration

• After 15 days, the plasma concentration becomes steady
  • Maximum Concentration: 374 ng/mL
  • AUC: 6943 ng.h/mL
• The Data is different in people who are fasting
  • The Maximum Concentration decreased by 26%
  • AUC decreased by 10%

Excretion

• About 64.5% of the administered dose is excreted in the feces
• About 16.4% of the administered dose goes through the urine

Distribution

• Central Volume of Distribution is approximately 1092 L
• Peripheral Volume of Distribution is approximately 1100 L

Adverse Reactions

Differentiation Syndrome

• May result in some "life-threatening symptoms" known as differentiation syndrome
  • Contact doctor immediately if any of these symptoms occur:
  • Fever, cough rash, rapid weight gain, vertigo, urination problems, joint swelling, difficulty breathing, chest pain, or joint pain

Side Effects

• If persists, call a doctor:
  • joint/muscle pain, severe tiredness, acute vomiting and nausea, diarrhea, mouth sores, loss in taste/ appetite, headache or insomnia
• More Serious
  • Seizures, difference in heartbeat, persisting pain in the abdomen region that could spread to the back

IV Compatibility

• There is limited information about Gilteritinib's compatibility with IV transfusions

Pharmacology

• Inhibited the receptor tyrosine kinase which regulates FLT3 in acute myeloid luekemia

Trials

• Phase 1 and 2:
  • Complete response: 41%
  • Overall Response Rate: 52%
  • Duration of Response(Median): 20 weeks
  • Overall Survival(Median): 31 weeks

• Phase 3:
  • Complete Remission
  • Complete Remission with limited blood recovery: 21% of patients

Brand Names

• Xospata

Names of Drugs that Look Alike

• There is limited information on Gilteritinib look-alike drugs

Price

Contraindicated Medications

{{MedCondContrAbs |MedCond = NameOfTheContraindication|Drug1|Drug2|Drug3}}